Novo Nordisk Pharmaceuticals Inc.

Recently-established subsidiary will have direct responsibility for registration and marketing of Novo Nordisk drug products in the U.S. The two Danish firms Novo and Nordisk merged in 1989. The NNPI detail force of 150 reps will continue to perform the marketing activities previously conducted by Squibb-Novo, a joint venture set up in 1982 to handle the sales of Novo's insulin in the U.S. Squibb will continue to store and distribute orders for all Novo Nordisk diabetes care products, while the SquibbMark unit will provide merchandising support.